Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab (TAK-079) in individuals with persistent or chronic primary immune thrombocytopenia (ITP). The study, known as TAK-079-1004 (NCT04278924), explored the impact of three different doses of subcutaneous mezagitamab versus placebo, administered […]
Oscotec has reported positive results from the phase 2 clinical trial of its SYK inhibitor cevidoplenib in patients with immune thrombocytopenia (ITP) who did not respond or relapsed after prior therapy. As per the South Korean-based clinical-stage pharma company, cevidoplenib has been studied in a randomized, placebo-controlled trial that featured 61 participants. The mid-stage clinical […]
Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase 3 trial for the treatment of immune thrombocytopenia (ITP) in pediatric patients. Avatrombopag is a thrombopoietin receptor agonist (TPO-RA). Its phase 3 study – AVA-PED-301 will assess the efficacy, safety, and pharmacokinetics in the treatment of the […]
Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune thrombocytopenia (ITP). This latest approval extends the drug’s use to children aged one year and older. The FDA’s endorsement of Nplate for pediatric ITP patients marks a significant milestone in treating this rare autoimmune disorder, characterized by […]
